Abstract

A use of an acceptor- less alcohol dehydrogenation catalyst for an electrocatalytic oxidation of an alcohol with an amine, to an imine by electrocatalytic synthesis under electrochemical conditions.

IPC Classes  ?

• C25B 1/02 - Hydrogen or oxygen
• C25B 1/23 - Carbon monoxide or syngas
• C25B 1/50 - Processes
• C25B 3/09 - Nitrogen containing compounds
• C25B 3/23 - Oxidation
• C25B 3/29 - Coupling reactions

Abstract

The present invention relates to novel photosensitive diazirine-conjugated phospholipids, and their use in delivering and releasing an active ingredient in a controlled manner, as well as photosensitive liposomes and controlled delivery systems comprising one or more photosensitive diazirine-conjugated phospholipids. The invention also relates to compositions and kits comprising said photosensitive liposomes, for use in various fields, such as for example in therapy, diagnosis, cosmetics, etc...

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 9/127 - Liposomes

Abstract

The present invention relates to a method for the synthesis of a solid mixed oxide containing oxides of nickel, magnesium and aluminium and optionally further containing an activator. Characteristically, an ionic solution A containing Ni2+, Mg2+and Al3+233 in a solvent selected from water, organic solvents and mixtures thereof, in particular alcohols and more particularly methanol, and further containing a surfactant, until a suspension is obtained, the solid particles thus obtained are separated and calcined at a temperature equal to or greater than 400°C in particular equal to 550°C.

IPC Classes  ?

• B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
• B01J 23/755 - Nickel
• B01J 23/889 - Manganese, technetium or rhenium
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 37/00 - Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
• B01J 37/03 - Precipitation; Co-precipitation
• B01J 37/06 - Washing
• B01J 37/08 - Heat treatment

Abstract

The present invention relates to novel peptides (cPEPs & altPEPs), to a method for the preparation thereof, and to the use thereof for modulating the accumulation of specific proteins.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The present invention generally relates to the reuse, reprocessing or recycling of silicone polymers. More precisely, the process of the present invention relates to a method for preparing organopolysiloxanes OR by a depolymerization reaction of at least one silicone S in the presence of an acid catalyst and at least one chain blocker Bc having at least one siloxane function. These organopolysiloxanes OR can subsequently be used in polymerization reactions or directly in various formulations.

IPC Classes  ?

• C08J 11/22 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds
• C08G 77/38 - Polysiloxanes modified by chemical after-treatment
• C08J 11/28 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic compounds containing nitrogen, sulfur or phosphorus
• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

Systems, devices, and methods for measuring the dynamic properties of metamaterials at the microscale are provided. For example, laser-induced resonant acoustic spectroscopy (LIRAS) can be used as a non-destructive and/or non-contact optical framework within a material of interest to measure photoacoustic excitation of elastic waves. The system can include a pulsed-laser-based mechanical characterization technique that emits lasers at the sample of interest from various directions to demonstrate a high-throughput non-contact framework that employs MHz-wave propagation signatures to create a vibrational response. The vibrational response of the sample of interest can be used to extract dynamic mechanical properties thereof, such as omnidirectional elastic information, damping properties, and defect quantification. In some embodiments, the LIRAS technique can be employed in a characterization module within an additive manufacturing system to measure parameters of printed parts.

IPC Classes  ?

• G01N 29/24 - Probes
• B22F 12/90 - Means for process control, e.g. cameras or sensors
• B33Y 50/00 - Data acquisition or data processing for additive manufacturing
• G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis

Abstract

The present invention relates to new peptides (cPEPs), a method for their preparation, and their use for modulating the accumulation of specific proteins.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

2 2xy2xy2xy22xyy, without the plastic material, that is suitable for degrading another plastic material.

IPC Classes  ?

• B09B 3/50 - Destroying solid waste or transforming solid waste into something useful or harmless involving radiation, e.g. electro-magnetic waves
• C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material
• B01J 21/06 - Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
• B01J 23/02 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the alkali- or alkaline earth metals or beryllium
• B01J 23/40 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of noble metals of the platinum group metals
• B01J 23/50 - Silver
• B01J 23/70 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper
• B01J 35/39 - Photocatalytic properties
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/08 - Heat treatment
• B09B 101/75 - Plastic waste

Abstract

The invention relates to a process for manufacturing a part made of a composite material having a ceramic matrix, the process involving: - infiltrating a pre-densified fibrous structure comprising a powder composition with a molten infiltration composition comprising silicon to form a ceramic matrix in a residual porosity of the pre-densified fibrous structure, the pre-densified fibrous structure comprising a pre-densification matrix comprising silicon carbide, and the powder composition comprising core-shell particles (1) having a silicon carbide core (3) and a shell having at least one layer (5; 51; 52) of boron-doped carbon containing boron at an atomic proportion of 5% to 20%.

IPC Classes  ?

• C04B 35/577 - Composites
• C04B 35/565 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbides based on silicon carbide
• C04B 35/573 - Fine ceramics obtained by reaction sintering
• C04B 35/628 - Coating the powders
• C04B 35/80 - Fibres, filaments, whiskers, platelets, or the like
• C04B 35/63 - Preparing or treating the powders individually or as batches using additives specially adapted for forming the products

Abstract

The invention relates to a pipette tip (1, 1') comprising at least one wall portion (2, 2') having a conical shape that is rotationally symmetrical about axis (R), characterized in that said wall portion (2, 2') comprises at least one first wall (20, 20') continuing on a periphery of at least one portion of an inner surface, said first wall projecting from a base (200, 200') in contact with said inner surface to a vertex (201, 201') at an angle of between 40° and 140° with respect to said wall portion (2, 2').

IPC Classes  ?

• B01L 3/02 - Burettes; Pipettes

Abstract

The present invention relates to the combination of a nucleic acid encoding a short isoform of rod- derived cone viability factor (RdCVF), a nucleic acid encoding a long isoform of rod-derived cone viability factor (RdCVFL) and a nucleic acid encoding a mutated form of the subunit 1 of G-protein- gated inwardly rectifying potassium channel (GIRK1) (GIRK1 F137S) or a mutated form of the subunit 4 of G-protein-gated inwardly rectifying potassium channel (GIRK4) (GIRK4 S143T), the three nucleic acids being expressed through one, two or three viral vectors, and said vectors may be within a single pharmaceutical composition or within several different pharmaceutical compositions (two or three). It also deals with the treatment of a retinal degenerative disease, in particular retinitis pigmentosa, with said viral vectors or pharmaceutical compositions.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants

Abstract

The present invention relates to a method for imaging an anatomical structure in a subject in need thereof, comprising the following steps: a) providing an injectable pharmaceutical composition comprising, as a contrast agent, at least one nanoparticle having a mean hydrodynamic diameter below 10 nm and comprising:. a biocompatible matrix, such as polyorganosiloxane,. at least one chelating agent covalently bonded to said biocompatible matrix,. at least one element having a Z of at least 40, chelated to at least a part of the chelating agents, b) injecting an effective amount of said pharmaceutical to said subject, and, c) acquiring an imaging scan of an anatomical structure of said subject in need thereof, by Spectral Photon Counting Computed Tomography (SPCCT) scanning.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 49/04 - X-ray contrast preparations
• A61K 49/08 - Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations characterised by the carrier
• A61K 49/18 - Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 35/00 - Antineoplastic agents

Abstract

Osteoarthritis (OA) is a type of degenerative joint disease that results from breakdown of joint cartilage and underlying bone. Here, the inventors studied the effects of intra-articular anti-GD3 monoclonal antibody injection. The present invention relates to a method for treating osteoarthritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a GD3 inhibitor.

IPC Classes  ?

• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

Inventors have used three cohorts of horses: a cohort consisting of healthy horses (n=20), a cohort consisting of horses hospitalized for colic without signs of sepsis until discharge (n=17) and horses hospitalized for colic with signs of sepsis (n=20). They performed western blot analysis and confirmed the presence of O-GlcNAc in the blood of the horses and showed that, that the O-GlcNAc levels in septic horses tended to decrease between admission and the first day (D1) after admission. This decrease became significant from the second day (D2) of hospitalization. Accordingly, the invention relates to a method for diagnosing whether a horse is at risk of or is susceptible to have a risk of sepsis comprising following steps: i) quantifying the expression level of O-GlcNAcylation in a biological sample obtained from the horse; ii) comparing the expression level quantified at step i) with its predetermined reference value; and iii) concluding that the horse is at risk of or is susceptible to have a risk of sepsis when the expression level of O-GlcNAcylation quantified at step i) is lower than its predetermined reference value.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

nrr , nii Qrr , Qii i ) and normalized three-dimensional magnetization vector (I) are accurately obtained.

IPC Classes  ?

• G01N 21/21 - Polarisation-affecting properties

Abstract

in vitroin vitro, the present inventors have shown that a combined therapy using HA15, a benzene sulfonamide thiazole compound, and an anticancer treatment such as an immunotherapeutic agent, a chemotherapeutic agent or targeted therapies significantly improves the survival rate and strongly reduces tumor growth as compared to monotherapies comprising either a benzene sulfonamide thiazole compound or an anticancer agent alone.

IPC Classes  ?

• A61K 31/18 - Sulfonamides
• A61K 31/426 - 1,3-Thiazoles
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a high-pressure method for preparing a metal monolith either as dense or as highly porous form, by rapid inductive heating hot pressing equipment. The method of the invention allows to obtain a metal monolith from metal powder without binder or any other additives

IPC Classes  ?

• B22F 3/00 - Manufacture of workpieces or articles from metallic powder characterised by the manner of compacting or sintering; Apparatus specially adapted therefor
• B22F 3/11 - Making porous workpieces or articles
• B22F 3/14 - Both compacting and sintering simultaneously
• B22F 1/06 - Metallic powder characterised by the shape of the particles
• B22F 1/065 - Spherical particles
• B30B 15/02 - Dies; Inserts therefor or mountings thereof; Moulds
• B30B 15/34 - Heating or cooling presses or parts thereof
• C22C 1/05 - Mixtures of metal powder with non-metallic powder
• C22C 47/14 - Making alloys containing metallic or non-metallic fibres or filaments by powder metallurgy, i.e. by processing mixtures of metal powder and fibres or filaments
• C22C 49/02 - Alloys containing metallic or non-metallic fibres or filaments characterised by the matrix material
• C22C 49/14 - Alloys containing metallic or non-metallic fibres or filaments characterised by the fibres or filaments

Abstract

48481436141414142214141414141414144)alkoxy group. The present invention further related to a pharmaceutical composition comprising it and to its use in the prevention and/or the treatment of pain.

IPC Classes  ?

• C07D 215/40 - Nitrogen atoms attached in position 8
• C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
• C07D 237/30 - Phthalazines
• C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine

Abstract

The present invention relates to the treatment alpha-synucleinopathies. In this study, the inventors showed that restoring brain cholesterol pathway and defective autophagy by AAV- CYP46A1 delivery, as evidenced in several neurodegenerative pathologies, could be a relevant therapeutic approach in alpha-synucleinopathies and particularly in PD. Thus the present invention relates to a vector for use in the treatment of alpha-synucleinopathies, which vector comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.

IPC Classes  ?

• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 35/76 - Viruses; Subviral particles; Bacteriophages
• A61K 35/761 - Adenovirus
• A61K 35/763 - Herpes virus
• A61K 38/44 - Oxidoreductases (1)

Abstract

A microstructured substrate comprising a main body and a plurality of elongated elementary microstructures extending from the main body, wherein the microstructured substrate comprises a plurality of nanowires positioned on at least one area of the surface of the main body and on the surface of the elementary microstructures that extend from the main body over said area.

IPC Classes  ?

• H01G 11/26 - Electrodes characterised by their structure, e.g. multi-layered, porosity or surface features
• H01G 11/28 - Electrodes characterised by their structure, e.g. multi-layered, porosity or surface features arranged or disposed on a current collector; Layers or phases between electrodes and current collectors, e.g. adhesives
• H01G 11/46 - Metal oxides
• H01G 11/70 - Current collectors characterised by their structure
• H01M 4/04 - Processes of manufacture in general
• H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 10/04 - Construction or manufacture in general
• H01M 4/134 - Electrodes based on metals, Si or alloys

Abstract

FT{ΔTenppee(ω)) (5a, 5b, 5c) from said first Fourier transform

IPC Classes  ?

• G01R 29/08 - Measuring electromagnetic field characteristics
• G01N 25/72 - Investigating presence of flaws

Abstract

22120320620312032062020 aromatic radical, which may be substituted or unsubstituted; for the polymerization of conjugated dienes, in particular the stereospecific polymerization of 1,3-dienes, especially butadiene and isoprene.

IPC Classes  ?

• C08F 4/70 - Iron group metals, platinum group metals, or compounds thereof
• C08F 136/04 - Homopolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds the radical having only two carbon-to-carbon double bonds conjugated

Abstract

The subject matter of the present invention is a method for producing such components, the components that can be obtained by this method and the use of these components in the production of a liquid organic electrolyte electrochemical cell.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
• H01M 50/414 - Synthetic resins, e.g. .thermoplastics or thermosetting resins
• H01M 50/446 - Composite material consisting of a mixture of organic and inorganic materials

Abstract

Disclosed are crystalline hafnium oxide nanoparticles, a method for manufacturing same, and the uses thereof. The invention relates to crystalline hafnium oxide nanoparticles, characterized in that they bear amide molecules and/or at least one amide degradation product chosen from a carboxylic acid, an amine or an amino acid and/or residues of said molecules on their surface.

IPC Classes  ?

• C01G 27/00 - Compounds of hafnium

Abstract

Chronic nephropathies, in particular tubulointertial nephropathy or tubulointertial nephropathy with fibrosis feature represent a real global public health concern. In particular, nephronophthisis (NPH) is an orphan genetic disease affecting the kidney. This recessive affection usually manifests with polyuria followed by a gradual reduction in kidney function related to progressive renal scarring. To date, no treatment is available for this affection. Now the inventors show that inhibition of the Hippo signalling pathway represents a new therapeutic avenue for the treatment of chronic nephropathies such as NPH. In particular, the inventors show that inhibition of MST1/2 or LATS1/2 reduces the NPH pro-inflammatory signature in mIMCD-3 renal cells even in response to uropathogenic bacteria. Thus the present invention relates to use of inhibitors of the Hippo signalling pathway for the treatment of chronic nephropathies.

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to a process for the fluorination and/or cyclization of an amino alkene or alkyne in a continuous-stream microreactor. The invention also relates to a facility for performing such a process.

IPC Classes  ?

• C07D 209/08 - Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• C07C 311/00 - Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
• C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
• C07D 211/38 - Halogen atoms or nitro radicals
• C07D 215/06 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
• C07D 279/02 - 1,2-Thiazines; Hydrogenated 1,2-thiazines
• C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
• C07D 519/04 - Dimeric indole alkaloids, e.g. vincaleucoblastine
• C07D 213/12 - Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles from unsaturated compounds
• C07C 209/74 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by halogenation, hydrohalogenation, dehalogenation, or dehydrohalogenation
• C07C 303/40 - Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups

Abstract

The present application relates to ceramic/polymer hybrid solid electrolytes with improved interfacial strength, comprising a surface-dehydrated pre-treated ceramic.

IPC Classes  ?

• H01M 10/056 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes
• H01M 10/052 - Li-accumulators
• H01M 6/18 - Cells with non-aqueous electrolyte with solid electrolyte

Abstract

The invention provides a pharmaceutical composition in oral liquid form, comprising vinorelbine, or a pharmaceutically acceptable salt thereof, and a cyclodextrin that is sulfobutylether-beta-cyclodextrin (SBE-beta-CD), preferably wherein at least 95%, vinorelbine, or said pharmaceutically acceptable salt thereof, is in form of an inclusion complex with said cyclodextrin.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/08 - Solutions
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The present invention relates to the adoptive therapy using notably CAR-T cells. Here the inventors used a lentiviral vector approach to silence RINF expression in a shRNA- dependent manner and evaluate the consequences of RINF silencing on human CAR-T cells proliferation ex vivo and their functionality and capacity to eradicate tumor cells in vivo. More, the proposed methodology to improve CAR-T cells persistence and efficacy by disrupting RINF/CXXC5 is not restricted to patients suffering from hematological or solid cancers (anti- CD19, anti-EGFR, anti-BCMA…) but could be also used to improve the efficacy of ACT in non-cancer diseases by such as lupus (1), cardiac fibrosis (2) or aging related-disorders (3). Thus, the present invention relates to an immune cell characterized in that it is defective for RINF.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention primarily relates to a biobased polyurethane resin composition, characterised in that it is obtained by mixing a volume V1 of polyisocyanate phase and a volume V2 of polyol phase, and in that: - either the polyisocyanate phase includes at least two polyisocyanates, at least one of which is an isocyanate-terminated prepolymer that comprises at least 70% biobased carbons and the other comprises at least 60% biobased carbons, and the polyol phase includes at least one polyol that comprises at least 80% biobased carbons, - or the polyol phase includes at least two polyols that each comprise at least 80% biobased carbons, and the polyisocyanate phase includes at least one isocyanate-terminated prepolymer that comprises at least 70% biobased carbons. Preferentially, the number of isocyanate functions in the polyisocyanate phase is equal to the number of alcohol functions in the polyol phase. The invention also relates to a method for manufacturing such a composition, which method advantageously involves evaluating the equivalent reactive volumes of each compound. The invention lastly relates to a printed support at least partially covered with a dome of resin, which dome of resin is produced from said polyurethane resin composition.

IPC Classes  ?

• C08G 18/10 - Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
• C08G 18/36 - Hydroxylated esters of higher fatty acids
• C08G 18/48 - Polyethers
• C08G 18/66 - Compounds of groups , , or
• C08G 18/72 - Polyisocyanates or polyisothiocyanates
• C08G 18/79 - Nitrogen characterised by the polyisocyanates used, these having groups formed by oligomerisation of isocyanates or isothiocyanates
• C09D 175/04 - Polyurethanes
• C09D 175/08 - Polyurethanes from polyethers
• C08L 75/04 - Polyurethanes

Abstract

The invention relates to the use of a lipophilic derivative of an aminopolycarboxylic acid as an extractant to extract at least one rare earth from an acidic aqueous solution. Applications: production of rare earths from concentrates derived from urban ores and, in particular, from concentrates from waste electrical and electronic equipment such as used or discarded NdFeB permanent magnets; production of rare earths from concentrates derived from natural ores or from concentrates derived from residues of natural ores.

IPC Classes  ?

• C22B 59/00 - Obtaining rare earth metals
• C22B 3/28 - Amines
• C22B 3/32 - Carboxylic acids
• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Abstract

The present disclosure is related to systems and methods of enzymatic degradation of crystallizable polymers or copolymers and PC/IPM containing crystallizable polymers or copolymers.

IPC Classes  ?

• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
• C08J 11/06 - Recovery or working-up of waste materials of polymers without chemical reactions
• C12N 9/18 - Carboxylic ester hydrolases
• C12N 9/20 - Triglyceride splitting, e.g. by means of lipase
• C12N 9/50 - Proteinases
• C12N 9/80 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides
• B29B 17/00 - Recovery of plastics or other constituents of waste material containing plastics
• B02C 19/00 - Other disintegrating devices or methods

Abstract

The invention relates to an optical substrate (1) having an integrated waveguide (2), at least one antenna (330) being formed in the optical substrate (1), the at least one antenna being formed by a plurality of nanoholes (341, 342, 343), at least one of the nanoholes (341, 342, 343) differing from the other nanoholes (341, 342, 343) by at least one of: its diameter, its spacing of the waveguide (2) in the height direction of the optical substrate (1), and its distance from an adjacent nanohole of the same antenna in the longitudinal direction of the optical substrate (1). The invention also relates to a spectrometer (S) that integrates an optical substrate (1) of this kind.

IPC Classes  ?

• G02B 6/12 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
• G02B 6/124 - Geodesic lenses or integrated gratings
• G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means

Abstract

Method for determining an amount of lithium contained in a biological fluid, said method comprising the steps consisting in adding, to a biological fluid sample of known volume, a given volume of a discriminating solution, the effect of which is to obtain a biological fluid solution buffered at a pH of between 6 and 8 and to bring about precipitation of at least a portion of the cations contained in the biological fluid sample except for the lithium Ions. The method further comprises the steps consisting in depositing a given volume of biological fluid solution onto an active layer (2) of an optode (1), said active layer comprising a chemical transducer of which at least one optical property is modified In the presence of lithium ions in the biological fluid solution, in measuring at least one characteristic of at least one light wave emitted or reflected by the active layer of the optode and in determining, from the at least one measured characteristic and from calibration data, an amount of lithium contained in the biological fluid.

IPC Classes  ?

• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
• G01N 21/82 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a precipitate or turbidity

Abstract

The present invention relates a therapeutic combination of a BTN3A activating antibody, a Bcl-2 family inhibitor and hypomethylating agents that is particularly useful for the treatment of cancer, in particular hematological malignancies. The present disclosure more particularly relates to the combined use of a BTN3A activating antibody that activates the cytolytic function of Vγ9Vδ2 T cells, and of Venetoclax, which selectively inhibits the Bcl2 receptor, and hypomethylating agents such as Azacytidine, to promote synergistically and specifically Vγ9Vδ2 T cell anticancer activity.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Circulatory failure generates hypoxia and leads to accumulation of reductive species in tissue and circulatory failure monitoring tools are needed but rare. Cardiopulmonary bypass (CPB) is known to promote brief circulatory failure during its initiation. In the present study, the Inventors demonstrate a correlation between whole blood redox potential and circulatory failure during (CPB). They made a prospective study with 17 patients eligible for cardiac surgery with cardiopulmonary bypass. They demonstrated a frank reduction of the whole blood redox potential during circulatory failure during the initiation of CPB. They also demonstrated that they were able to classify patients in 3 groups, one of them presenting an unfavorable post-operative outcome. Accordingly, the present invention relates to a method of diagnosing acute circulatory failure in a patient comprising determining the level of redox potential in a sample obtained from said patient, wherein the level of redox potential indicates whether the patient suffers or not from an acute circulatory failure.

IPC Classes  ?

• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

Deposition of a material such as indium in the form of nitrided thin layers, by evaporation and dual activation using a nitrogen plasma (41) and an electron beam (42).

IPC Classes  ?

• C23C 14/00 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
• C23C 14/06 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the coating material
• C23C 14/26 - Vacuum evaporation by resistance or inductive heating of the source
• C23C 14/24 - Vacuum evaporation
• C23C 14/32 - Vacuum evaporation by evaporation and subsequent ionisation of the vapours
• H01J 37/32 - Gas-filled discharge tubes

Abstract

The invention relates in particular to a cell culture device comprising an insert (1) having an internal cavity (11) delimited by an insert side wall (12) and an insert bottom (10), said internal cavity being able to receive said cell culture in a cell culture fluid so as to create a cell tissue (2). The device comprises a container (3) that removably receives said insert, said side wall (12) having first through-holes (13). The container comprises an internal flue (30) and an opening (33) which allows said insert (1) to be inserted into said flue. The insert bottom comprises second through-holes (14) allowing observation of the cells therethrough, said first and second through-holes being capillary holes able to retain said cell culture fluid in said internal cavity and serving to anchor said cell tissue.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means

Abstract

A method for optimizing a quantum operation to be applied on two quantum objects of a system of quantum objects The present invention relates to a method for optimizing a quantum operation to be applied on at least two quantum objects (12) of a system (10) of quantum objects, the method comprising the determination of an optimized pulse to be generated by at least one controlled laser for implementing the quantum operation on the at least two quantum objects (12) while fulfilling a robustness criterion, the at least two quantum objects (12) having a quantum state depending on the excitation level of the at least two quantum objects, the excitation level being chosen between 01, 10 and 11, 0 defining a de-excited state for a quantum object and 1 defining an excited state for a quantum object, the quantum state having a zero order term and a first order term.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The invention relates to an optical device for the full-field optical coherence tomography microscopic imaging of at least one sample, the device comprising a lens for observing the sample when in use, the device comprising a specular interface, the device thus being able, when in use, to allow the production of at least one interference between at least one reference wave obtained by the reflection of light emitted by a light source associated with the device from the specular interface, and at least one object wave obtained by the backscattering of the light emitted by the source from the sample, the specular interface being arranged with respect to the lens in such a way that, when in use, the object wave passes through the specular interface on its path between the sample and the source. The invention also relates to the corresponding facility and method.

IPC Classes  ?

• G01B 9/02056 - Passive reduction of errors
• G01B 9/02091 - Tomographic interferometers, e.g. based on optical coherence
• G01B 9/04 - Measuring microscopes
• G01N 21/47 - Scattering, i.e. diffuse reflection
• G02B 21/00 - Microscopes
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

One aspect of the invention relates to a method (100) for controlling a mechatronic system, based on a model for predicting the behaviour of the mechatronic system and a cost function ensuring compliance with constraints by the mechatronic system, with a view to following path instructions to a prediction horizon, the method comprising: reformulating (10) the constraints into barrier functions and integrating the barrier functions into the cost function; and for each sampling period of a sequence of sampling periods: obtaining (20) the path instructions and at least one measurement of the mechatronic system in a current state; determining (30) coefficients of a polynomial of order m using a Nelder-Mead method optimizing the cost function based on the predicting model, this determining step receiving as input the path instructions and the at least one measurement of the mechatronic system obtained (20); computing (40) a command through evaluation of the polynomial; and applying (50) the command to the mechatronic system.

IPC Classes  ?

• G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
• G05B 13/04 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric involving the use of models or simulators

Abstract

transOPA1e.g., ex vivoin vivoOPA1OPA1 mutations.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61P 27/02 - Ophthalmic agents
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to the method for producing a three-dimensional (3D) model of multiple myeloma (MM), in the form of spheroids, by co-culturing stem cells/mesenchymal stromal cells, endothelial progenitors and primary plasma cells of one or more MM patients. The present invention also relates to the spheroids obtained by said method, and uses thereof.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0781 - B cells; Progenitors thereof
• C12N 5/0775 - Mesenchymal stem cells; Adipose-tissue derived stem cells

Abstract

The present invention relates to a method for ultrasound imaging of a microvascular structure, which method characterised in that it comprises: - a step of injecting ultrasound contrast agents into blood vessels in a region comprising a microvascular structure, - a step of ultrasound imaging the region comprising the microvascular structure while the contrast agents flow through the blood vessels, the concentration of the contrast agents and/or the ultrasound frequency of the imaging being chosen such that the contrast agents are sufficiently separated to prevent feedback, - a step of detecting/filtering and locating the contrast agents, - a step of individually monitoring the contrast agents, - a step of classifying the behaviours of the individually monitored contrast agents according to at least one predetermined behaviour characteristic of contrast agents flowing through the microvascular structure, and - a step of imaging the microvascular structure according to the thus-performed classification.

IPC Classes  ?

• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
• A61B 8/06 - Measuring blood flow

Abstract

The present invention relates to a kit and an in vitro method for detecting and characterizing the degradation of a particular organ or tissue, on the basis of the analysis of the presence of at least one specific methylated cell-free DNA in a biological sample. More particularly, the invention relates to a kit and a method for detecting and characterizing the degradation of an organ selected from: the brain, the lung and the kidney, and/or of a tissue present in this organ. The invention also relates to a method for the in vitro diagnosis of a disease or condition involving the lysis of an organ or tissue.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

222 in a sample, wherein the sample comprises a persistent luminescence nanoparticle.

IPC Classes  ?

• G01N 21/64 - Fluorescence; Phosphorescence
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
• C01G 15/00 - Compounds of gallium, indium, or thallium
• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
• G01N 21/76 - Chemiluminescence; Bioluminescence
• G01N 21/70 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light mechanically excited, e.g. triboluminescence
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Abstract

The invention relates to a method (100) for assisting the determination of a dosage of antioxidants to be administered to a patient suffering from oxidative stress, said method (100) comprising at least one iteration of a prediction phase (108) comprising the following steps: - measurement (110), on a blood sample previously taken from said patient, of a level of at least the following input parameters: cholesterol level, zinc level, copper level, vitamin C level, vitamin E level, and selenium level; - estimation (130) of a dosage for at least one antioxidant to be administered to said patient, via a previously trained estimation model, executed by a calculation unit, said estimation model taking as input said at least one input parameter. The invention also relates to a device which implements such a method.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

The present invention relates to a microfluidic device and to a method for applying at least one hydrodynamic stress of defined intensity and duration to cells in suspension, said cell being in motion in said device, and for characterizing the morphology and the physiological state of these cells during, and optionally after, the application of the hydrodynamic stress.

IPC Classes  ?

• G01N 15/14 - Electro-optical investigation
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers

Abstract

The present invention relates to a method for producing or identifying one or several shared cancer epitope(s), as well as peptides comprising or consisting of the epitopes identified or produced by said method, expression vectors encoding said peptides, cytotoxic T lymphocytes (CTLs) generated in vitro by stimulation of T cells with the said peptides or vectors, CTLs of a subject treated with said peptides or vectors, and engineered T cells expressing T-cell receptors recognizing said peptides. The present invention also relates to the use of said peptides, expression vectors, CTLs or engineered T cells as a vaccine or a medicament, and in particular, the use of said peptides, expression vectors, CTLs, or engineered T cells for preventing or treating at least one cancer in a subject in need thereof.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants

Abstract

Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 9/51 - Nanocapsules
• A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 38/13 - Cyclosporins
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/515 - Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61P 17/00 - Drugs for dermatological disorders

Abstract

123412344, other than hydrogen, comprise from 1 to 30 carbon atoms, optionally substituted with at least one of the groups or substituents.

IPC Classes  ?

• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61Q 19/00 - Preparations for care of the skin
• C10M 105/00 - Lubricating compositions characterised by the base-material being a non-macromolecular organic compound

Abstract

The present invention relates to a process for tanning hides using a tanning solution that comprises a silicon compound and is free from metals. The invention also relates to a method for preparing leather that includes a tanning process of this type. The invention also relates to tanned hides obtained by such a tanning process. The invention further relates to a process for detanning the hides obtained by means of the above tanning process.

IPC Classes  ?

• C14C 3/08 - Chemical tanning by organic agents

Abstract

5242323333.

IPC Classes  ?

• C07F 5/06 - Aluminium compounds
• C07F 15/02 - Iron compounds
• B01D 53/02 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
• B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material

Abstract

The invention relates to an elementary particle detector (1) comprising: dynodes (10) capable of converting an elementary particle into an avalanche of electrons; conductive grids (30) through which accelerated electrons are able to pass, each grid being defined by a unique electric potential, each unique electric potential being chosen so that the unique electric potential of said conductive grid (30) is strictly lower than the unique electric potential applied to the conductive grid (30) immediately thereafter in the direction of detection (X); at least one signal sensor (50) able to measure an electric signal (S) produced by the accelerated electrons when they pass through the conductive grids (30); and a control unit (90) configured to determine, on the basis of the electric signal (S), a conversion dynode (18) at which the conversion of the elementary particle has taken place. The invention further relates to an elementary particle detection method.

IPC Classes  ?

• H01J 43/24 - Dynodes having potential gradient along their surfaces
• H01J 43/30 - Circuit arrangements not adapted to a particular application of the tube and not otherwise provided for
• H01J 47/02 - Ionisation chambers

Abstract

The invention relates to a process for programing a single cell or a group of cells to become malignant, comprising the following steps a) providing cell(s) with the following features: o expressing a dedifferentiation factor, and o comprising an oncogene whose expression is inducible, and b) inducing the expression of said oncogene.

IPC Classes  ?

• A01K 67/027 - New breeds of vertebrates
• C07K 14/82 - Translation products from oncogenes
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The invention relates to a method for bringing a virtual three-dimensional model of a target organ, which model is called the 3D model, into register with at least one image of said target organ in a scene, said image being obtained by an endoscope (12), the method in particular comprising: a step of predicting a position and orientation of the target organ relative to the scene; a step of superposing at least one current endoscope image with a see-through projection of the 3D model as a function of the predicted position and orientation, on a display device (18); a step of receiving a command indicating an alignment between the see-through projection of the 3D model and the image of the target organ in the current image; and a step of computing the position and orientation of the target organ in the current image relative to the scene.

IPC Classes  ?

• G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods

Abstract

Device (10) capable of being installed on a satellite (1), comprising telecommunication means (13) for broadcasting information directly to at least one telecommunication terminal (2) on the ground. The information is broadcast according to a Bluetooth Low Energy protocol, and in AD mode. The device can be used in particular for an Earth observation satellite.

IPC Classes  ?

• H04W 4/06 - Selective distribution of broadcast services, e.g. multimedia broadcast multicast service [MBMS]; Services to user groups; One-way selective calling services
• H04W 4/90 - Services for handling of emergency or hazardous situations, e.g. earthquake and tsunami warning systems [ETWS]
• H04B 7/185 - Space-based or airborne stations
• H04W 56/00 - Synchronisation arrangements

Abstract

The invention relates to a method for producing an abradable ceramic composite coating on a substrate, the method comprising: obtaining (E1) a composition (30) in powder form comprising a matrix powder and a ceramic filler hydrated precursor powder having a lamellar crystallographic structure, wherein the ceramic filler powder represents from 5 to 40% of the combined volume of the matrix powder and the ceramic filler powder; compressing the prepared powder composition at a pressure greater than 150 MPa; and a step of reactive sintering (E2) the obtained powder composition, during which the pressure is maintained at a temperature of less than 550°C, and the particles of the matrix powder in the sintered powder composition have an aspect ratio of 2 or greater. The invention also relates to an abradable ceramic coating obtained according to the method. The invention also relates to a superalloy part for a turbomachine, for example a turbine part, comprising such a coating.

IPC Classes  ?

• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
• C04B 35/488 - Composites
• C04B 35/486 - Fine ceramics
• C04B 35/622 - Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
• C04B 35/645 - Pressure sintering
• C04B 38/00 - Porous mortars, concrete, artificial stone or ceramic ware; Preparation thereof
• C04B 41/52 - Multiple coating or impregnating
• C04B 41/87 - Ceramics
• C04B 41/89 - Coating or impregnating for obtaining at least two superposed coatings having different compositions
• B32B 18/00 - Layered products essentially comprising ceramics, e.g. refractory products
• F01D 11/12 - Preventing or minimising internal leakage of working fluid, e.g. between stages for sealing space between rotor blade tips and stator using a rubstrip, e.g. erodible, deformable or resiliently biased part
• C23C 24/08 - Coating starting from inorganic powder by application of heat or pressure and heat
• F01D 25/00 - Component parts, details, or accessories, not provided for in, or of interest apart from, other groups
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone

Abstract

The present invention relates to the treatment of cancer. Here, the inventors identified a subset of prostate cancer patients showing an up-regulation of the epigenetic enzymes SUV4-20H1 and SUV4-20H2, two methyltransferases responsible for the di- and tri- methylation of histone H4 at lysine 20 (H4K20me2/3). Consistent with this, the inventors demonstrate that the pharmacological inhibition of both SUV4-20H1 and SUV4-20H2 enzymes by the chemical compound A196 (14) leads to the complete loss of H4K20me2/3 states in prostate cancer cells. Although displaying epigenetic reprograming at genome-wide levels, cancer cells display any significant impairment in their survival or proliferation, thereby demonstrating that the inhibition of SUV4-20H1 and SUV4-20H2 is not toxic per se. Yet, the inventors showed that the pharmacological inhibition of SUV4-2H1 and SUV4-20H2 subtly affects DNA repair mechanisms and the levels of trapped topoisomerase II (TOPO2) complex in silent chromatin regions upon TOPO2 poisons. This creates in vitro as well as in vivo a lethal synergy between A196 and the TOPO2-poison etoposide in prostate cancer cells. Altogether, the results of the inventors showed that the simultaneous inhibition of SUV4-20H and TOPO2 enzymatic activity constitutes indeed a new therapeutic approach for the treatment of advanced or metastatic prostate cancers, which are particularly addicted to SUV4-20H2 and TOPO2 activities. Other cancers could also benefit of this drug combination, since the co-treatment of A196 and etoposide induces similar lethal synergy in other epithelial cancer cells such as breast cancer cell lines. Thus, the present invention relates to a combination of a SUV4-20H inhibitor and a TOPO2 inhibitor for use in the treatment of a cancer in a subject in need thereof.

IPC Classes  ?

• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to triblock polymers of formula A-B-C, in which the symbol A represents a polystyrene block, the symbol B represents a statistical copolymer block having a glass transition temperature of less than -10° C, the statistical copolymer comprising units of a 1,3-diene and more than 50 mol % of ethylene units, and the symbol C represents a polyethylene block having a melting temperature higher than 90°C. The triblock polymers according to the invention have good elastic recovery.

IPC Classes  ?

• C08F 295/00 - Macromolecular compounds obtained by polymerisation using successively different catalyst types without deactivating the intermediate polymer
• C08F 210/02 - Ethene
• C08F 297/08 - Macromolecular compounds obtained by successively polymerising different monomer systems using a catalyst of the ionic or coordination type without deactivating the intermediate polymer using a catalyst of the coordination type polymerising mono-olefins
• C08L 53/00 - Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers

Abstract

Among the strategies allowing cancer cells to escape the immune system, the presence of Transforming growth factor beta (TGF-β) in the tumor micro-environment (TME) is one of the most potent immunosuppressive mechanisms for many types of tumors. Thus, depleting TGF-β is regarded as a promising potent therapeutic approach to fight cancers, regardless of the type of tumor. However, the major impediment for achieving this objective is that TGF-β belongs to the few cytokines that must be activated once secreted. Moreover, a systemic targeting of TGF-β is associated with profound side effects due to TGF-β ability to sustain the homeostasis of numerous tissues. Hence, selectively targeting of TGF-β activation within the TME appears as a rational approach to boost the anti-tumor response and avoid side effects. The integrin αvβ8 expressed on Tregs specifically promotes TGF-β activation and impairs the anti-CD8 T cell response within the TME of different cancers in both mice and humans. The inventors generated anti-β8 chain of αvβ8 integrin (Itgβ8) neutralizing monoclonal antibodies which specifically bind to Tregs and selectively neutralize the ability of Tregs to activate the TGF-β. Thus, the present invention relates to isolated anti-Itgβ8 neutralizing antibodies which specifically binds to β8 chain of αvβ8 integrin (Itgβ8) expressed on Tregs, and their uses for treating cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

in vitroex vivoin vitroex vivoex vivo diagnosis of bacterial resistance by efflux, as well as specific coumarin derivatives for this use.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
• C12Q 1/18 - Testing for antimicrobial activity of a material

Abstract

The invention relates to a device for spraying ozonated water in an agricultural environment, the device comprising a collar defining a dispensing opening (4) for dispensing both water and ozone together, the water being sprayed by a nozzle (10) set back from the opening, the nozzle being supplied from a tank (7) installed with the device, the ozone gas being dispensed via a gas inlet (22) connected to a device for producing and/or storing gas (9, 13) which is also installed with the device, the gas inlet also being set back in the collar such that the collar defines a chamber (28, 29) for confining the ozone gas emitted around the sprayed liquid in order to allow the sprayed liquid to be enriched with dissolved ozone.

IPC Classes  ?

• B05B 7/04 - Spray pistols; Apparatus for discharge with arrangements for mixing liquids or other fluent materials before discharge
• B05B 1/34 - Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
• A61L 2/22 - Phase substances, e.g. smokes, aerosols
• A61L 9/14 - Disinfection, sterilisation or deodorisation of air using sprayed or atomised substances
• B05B 1/04 - Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to produce a jet, spray, or other discharge of particular shape or nature, e.g. in single drops in flat form, e.g. fan-like, sheet-like

Abstract

The invention relates to a method implemented by computer means for characterizing at least one organ of a patient in at least one medical image, said method comprising the following iterative steps of: segmenting (6) said organ in at least one image (7) representing a healthy organ, so as to obtain at least one segmentation mask (8) of said healthy organ, generating additional segmentation masks of said healthy organ, using at least one data augmentation method (9) on the basis of the segmentation mask obtained in step (a), said data augmentation method (9) being a shape-preserving method, training an autoencoder (10) with the segmentation mask obtained in step (a) and the additional segmentation masks obtained in step (b) to encode the shape of said organ in a latent space (11 ).

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

The present invention relates to a process for producing a stable PVDF latex by emulsion polymerization in the absence of fluorinated surfactant, said latex being stabilized by poly(vinyl alcohol) (PVOH).

IPC Classes  ?

• C08F 14/22 - Vinylidene fluoride
• C08F 261/06 - Macromolecular compounds obtained by polymerising monomers on to polymers of oxygen-containing monomers as defined in group on to polymers of unsaturated ethers
• C08L 27/16 - Homopolymers or copolymers of vinylidene fluoride
• C09D 127/16 - Homopolymers or copolymers of vinylidene fluoride
• C08L 29/04 - Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
• C08F 2/20 - Suspension polymerisation with the aid of macromolecular dispersing agents

Abstract

The present invention concerns a method and a system of fault tolerant preparation of quantum polar code states, comprising: -a set of single qubit Pauli measurement circuits (3) configured to prepare an initial quantum system 5 of N = 2n single-qubit states associated to an initial quantum base, -a set of two qubit Pauli measurement circuits (7) configured to recursively prepare a quantum polar code |q2n)s °f codelength N = 2n, wherein at each recursive level k, where k = 1 to n, a set of 2n/2k quantum polar code states ||<72fc) j(k) = 1 to 2n/2k of codelengths 2k, siW referenced by corresponding sets Sj^ of indices comprising first and second sets of frozen indices = [17, ■ ■■, i7(k)} and X7(k) = {(i + !);(/<),..., 27k k)} is prepared, each quantum polar code state |q2k) being prepared by the application of two qubit Pauli measurement P ® P circuits on two equivalent polar code states 2^ ) 01 aanndd belonging to the output of the antecedent recursive level k — 1 and referenced by two corresponding sets of iinnddiicceess

IPC Classes  ?

• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The invention relates to an angular positioning module (1) for a positioning system for an optical bench, the angular positioning module (1) comprising: a fixed frame (5); a rotating shaft (7); a rotary motor (11); a transmission device (17) being provided with a pulley (19) mounted on the output rod (13) of the rotary motor (11) so as to be coupled in rotation therewith, with a wheel (21) mounted on the rotating shaft (7) so as to be coupled in rotation therewith, and with a cable wound on the one hand around the pulley (19) and on the other hand around the wheel (21) such that the pulley (19) and the wheel (21) are connected by two separate strands of the cable, the rotation of the pulley (19) causing the winding of a first strand and the simultaneous unwinding of a separate second strand around the pulley (19), and vice versa.

IPC Classes  ?

• G02B 7/00 - Mountings, adjusting means, or light-tight connections, for optical elements
• F16H 19/06 - Gearings comprising essentially only toothed gears or friction members and not capable of conveying indefinitely-continuing rotary motion for interconverting rotary motion and reciprocating motion comprising an endless flexible member

Abstract

The invention relates to an electrical energy storage module (M1-ln) which comprises a plurality of elementary storage cells (C1 to C12). According to the invention, the module comprises at least one cell unit (U1-1, U1-2) including a plurality of elementary storage cells connected in series (C1 to C6; C7 to C12) and integrated power-switching means (P1, S1; P2, S2) dedicated to this cell unit, delivering, between two power output terminals (B1, B2) of the cell unit, a positive DC voltage, a negative DC voltage, a zero voltage or a high impedance state, depending on a command received by the cell unit.

IPC Classes  ?

• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells

Abstract

(n)jn(n)1(n)2(n)2(n) associated with each useful output (15u) and defined when the light source (11) is inactive.

IPC Classes  ?

• G01N 21/27 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
• G01B 9/02 - Interferometers
• G01N 21/45 - Refractivity; Phase-affecting properties, e.g. optical path length using Schlieren methods

Abstract

The present invention relates to the use of an aminoborane for the preparation of an alkenylaminoborane from a catalyst-free alkyne or in the presence of a catalyst selected from the group of acids consisting of carboxylic acids, sulfonic acids, sulfuric acid, phosphonic acids, phosphoric acid and hexafluoroisopropanol (HFIP), in particular acetic acid, benzoic acid and 4-(dimethylamino) benzoic acid, methylsulfonic acid, phosphoric acid, trifluoroacetic acid (TFA) and hexafluoroisopropanol (HFIP), and a preparation method therefor.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• C07F 7/08 - Compounds having one or more C—Si linkages
• C08K 5/55 - Boron-containing compounds

Abstract

Advanced cutaneous melanoma can be treated by immunotherapy targeting immune check points such as PD-1 and CTL-A4. However, 50% of patients do no respond because of primary or acquired resistance mechanism. Thus, new targets for addressing the treatment of said resistance are highly needed. The inventors show that TNF (Tumour Necrosis Factor) and ceramide metabolism alterations in melanoma cells contribute to melanoma progression and resistance to immunotherapies. In particular, the inventors demonstrate that TNF is a potent modulator of ceramide metabolism and TNF-mediated ceramide metabolism changes contribute to various biological processes such as cell proliferation, cell death and cell differentiation. Among the biological processes by which TNF triggers melanoma immune escape and resistance to immunotherapies, TNF triggers a dedifferentiation process of melanoma cells associated with the reduction of melanocytic antigen expression and epithelial to mesenchymal transition. Finally, the inventors show that glycosphingolipid pattern in plasma can predict the clinical outcome of advanced melanoma treated with ipilimumab and nivolumab. Accordingly, ceramide metabolites and metabolizing-enzymes can be new therapeutic targets and/or biomarkers in advanced melanoma patients treated with immunotherapies.

IPC Classes  ?

• A61K 31/225 - Polycarboxylic acids
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a magnetic component comprising a substrate (6) supporting at least one pair of permanent magnets (2) extending in a first direction (X), each magnet (2) having an interaction end (21a, 21b), the interaction ends (21a, 21b) being arranged facing one another, the pair of magnets (2) being arranged so as to exert an antisymmetric magnetic field with a high magnetic field gradient along a second direction (Z) orthogonal to the first direction (X), under the effect of a magnetic field produced by external magnetic means.

IPC Classes  ?

• H01F 41/34 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformers; Apparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for applying conductive, insulating or magnetic material on a magnetic film in patterns, e.g. by lithography
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The invention relates to a method for characterising the deformability of cells or a portion of cells in a sell sample, the method comprising: • - culturing the cells on a microstructured plate having microgrooves with a predetermined width and depth for at least partially engaging the nuclei of the cells in one or more microgrooves, at least one portion of the surface of the microgrooves being a cell adhesion surface; • - measuring a fluorescence signal of the nuclei, which nuclei are pre-treated so as to emit fluorescence radiation; • - on the basis of the fluorescence signal measured for each nucleus, determining a fluorescence intensity profile and at least one morphological parameter of the nucleus; • - on the basis of the fluorescence intensity profile and the at least one morphological parameter, determining a deformation class of the nucleus in the depth of the microgrooves.

IPC Classes  ?

• G01N 15/14 - Electro-optical investigation
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood

Abstract

A thermal energy storage device (1) comprises a storage unit, formed by a reservoir (3) for receiving a thermal energy storage material (5) and a closure device (2) configured to close the opening of the reservoir, and a sealing system for sealing the storage unit, said thermal energy storage material (5) consisting of anhydrous lithium hydroxide having a purity greater than 96% or lithium hydroxide monohydrate with a purity greater than 56%.

IPC Classes  ?

• F28D 20/02 - Heat storage plants or apparatus in general; Regenerative heat-exchange apparatus not covered by groups or using latent heat
• C09K 5/06 - Materials undergoing a change of physical state when used the change of state being from liquid to solid or vice-versa

Abstract

12344 are independently a hydrogen atom or an alkyl group, A is an alkylene group, and the total number of carbon atoms in the surfactant compound of formula (I) is from 10 to 24.

IPC Classes  ?

• B65G 5/00 - Storing fluids in natural or artificial cavities or chambers in the earth
• E21B 41/00 - Equipment or details not covered by groups
• C09K 8/584 - Compositions for enhanced recovery methods for obtaining hydrocarbons, i.e. for improving the mobility of the oil, e.g. displacing fluids characterised by the use of specific surfactants
• C09K 8/594 - Compositions used in combination with injected gas

Abstract

The invention relates to a method of extracting a bead from a droplet, comprising the steps of: – providing a droplet of a first fluid within a second fluid, the first fluid being immiscible with the second fluid, the droplet containing a bead; – passing the droplet through a constriction in a main channel, and supplying a third fluid second fluid immiscible with the first fluid in a downstream channel, downstream of the constriction so as to extract the bead from the droplet.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers

Abstract

The invention relates to a device and method for measuring an electromagnetic dosimetric quantity received by an object illuminated by an electromagnetic (EM) field (23) emitted by an electromagnetic source (2), comprising: - a screen (3) comprising a top surface (31) faced to the electromagnetic source (2) and a bottom surface (32) opposite to the top surface (31 ), said screen (3) being adapted to absorb at least a portion of the EM field emitted by the electromagnetic source (2); - the screen comprising a plurality unit cells (33); - at least one thermal sensor (5) arranged relative to the bottom surface of the screen (3) and configured to measure a physical quantity relative to the heat distribution along a surface of the screen induced due to the absorption of the electromagnetic field in the screen medium; - a processing unit (6) linked to the at least one thermal sensor (5) and configured to calculate the electromagnetic dosimetric quantities from the measured heat distribution, the information relative to the EM field emitted by the EM source, and the predetermined EM and thermal properties of the screen.

IPC Classes  ?

• G01R 29/08 - Measuring electromagnetic field characteristics

Abstract

The invention relates to methods for determining the methylation profile of DNA sequences of interest and methods for accurately distinguishing between a healthy methylation profile and a cancerous methylation profile, as well as to kits to implement them.

IPC Classes  ?

• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Abstract

The present invention relates to a method for depositing a continuous coating of aluminium oxide on a metal substrate by means of induction heating-assisted pressurised, temperature-controlled chemical deposition, the method comprising a solvothermal synthesis step based on an aluminium oxide precursor dissolved in a water-co-solvent mixture heated by induction to a temperature of between 400°C and 700°C and a pressure of between 1 MPa and 25 MPa. It also relates to a device (100) for depositing an aluminium oxide on a metal substrate (104) by means of pressurised, temperature-controlled chemical deposition, which device comprises: - an chamber (102) delimited by walls forming a closed volume (V), the chamber being intended to contain a heated and pressurised fluid, the material of the walls of the chamber being transparent to electromagnetic radiation; - a support (106) transparent to electromagnetic radiation intended to support the metal substrate (104) located inside the chamber; - an induction heating device (109) surrounding the outside of the chamber (102) so as to be able to heat the metal substrate (104) positioned on the support (106); - an inlet (116) located in the upper portion of the chamber (102) and configured to allow a precursor material previously dissolved in water to be added to the chamber (102); - an inlet (120) located in the lower portion of the chamber (102) and configured to allow a fluid to be added to the chamber (102); - at least one outlet (124) configured to purge the volume (V); - a sapphire window (112) arranged in the upper portion of the chamber, allowing the temperature of the metal substrate (104) to be controlled by a bichromatic pyrometer (114) arranged outside the chamber; - a set of polymer seals (200); - a metal assembly (202) rigidly screwed together by metal columns (204) containing a circulating fluid maintained, by a cryostat (206), at a temperature of 20°C.

IPC Classes  ?

• C23C 18/12 - Chemical coating by decomposition of either liquid compounds or solutions of the coating forming compounds, without leaving reaction products of surface material in the coating; Contact plating by thermal decomposition characterised by the deposition of inorganic material other than metallic material
• C01B 13/36 - Methods for preparing oxides or hydroxides in general by precipitation reactions in solutions
• C01F 7/448 - Dehydration of aluminium oxide or hydroxide, i.e. all conversions of one form into another involving a loss of water by wet processes using superatmospheric pressure, e.g. hydrothermal conversion of gibbsite into boehmite

Abstract

The invention relates to a nickel-based superalloy comprising, in weight percentages, 5.0 to 6.0% aluminium, 6.5 to 8.5% tantalum, 0 to 1.0% titanium, 1.0 to 4.0% cobalt, 5.0 to 8.0% chromium, 0 to 0.5% molybdenum, 3.0 to 4.0% tungsten, 3.75 to 5.75% rhenium, 3.5 to 5.0% platinum, 0.05 to 0.25% hafnium and 0 to 0.15% silicon, the remainder being made up of nickel and inevitable impurities. The invention also relates to a single-crystal blade (20A, 20B) comprising such an alloy and to a turbine engine (10) comprising such a blade (20A, 20B).

IPC Classes  ?

• C22C 19/05 - Alloys based on nickel or cobalt based on nickel with chromium
• F01D 5/28 - Selecting particular materials; Measures against erosion or corrosion

Abstract

In a first aspect, the present disclosure relates to a kit of parts, wherein the kit of parts may comprise a writing instrument comprising a plasmonic ink composition; and a synthetic paper.

IPC Classes  ?

• C09D 11/17 - Writing inks characterised by colouring agents
• C09D 11/18 - Writing inks for use in ball-point writing instruments

Abstract

12211; and F. determining a value of the scale factor S and a value of the offset O specific to the measurement of the spectrum of the output beam by means of the spectrometer on the basis of the variations in energy ΔE.

IPC Classes  ?

• H01J 37/22 - Optical or photographic arrangements associated with the tube

Abstract

The invention relates to a method for estimating the content of a gas-of-interest in a medium using a measurement device intended to be placed in contact with the medium, the device extending between a contact face intended to be applied against the medium and a distal end, the device comprising a side wall extending between the contact face and the distal end, and the device comprising: on the contact face, at least one intake opening configured to collect the gas-of-interest emitted by the medium, the intake opening extending through the contact face; a measurement chamber comprising a gas sensor, the gas sensor being configured to measure a concentration of the gas-of-interest flowing through the measurement chamber; a collection chamber (30) connected to the measurement chamber and delimited by the side wall, the collection chamber comprising at least one side opening (34) extending through the side face so as to admit ambient air into the collection chamber.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• A61B 5/083 - Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/1477 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using chemical or electrochemical methods, e.g. by polarographic means non-invasive
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

The invention relates to a probe comprising a bead, a first binding assembly and a second binding assembly, wherein: – the first binding assembly comprises a first bead-binding portion and a first probe portion, – the second binding assembly comprises a second bead-binding portion, a second probe portion, and a cleavable portion between the second bead-binding portion and the second probe portion, – the first and second bead-binding portions are attached to the bead; – the first probe portion is a portion capable of binding to a first analyte; – the second probe portion is a portion capable of binding to a second analyte.

IPC Classes  ?

• C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

ex vivoex vivo method to obtain improved CAR-T cells comprising the following steps i) cultivate T cells obtained from a subject with a FOXO1 inhibitor during a time of 2 to 10 days; ii) transforming the T cells into CAR-T cells thanks to a known method.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

Abstract

Rheumatoid arthritis (RA) is the most common form of inflammatory rheumatism involving small joints which are the seat for swelling and pain with structural damage, responsible for functional disabilities if no treatment is proposed. The inventors show that circulating MAIT cells were reduced and exhibited an activated and anti-apoptotic phenotype in RA patients compared to healthy controls. MAIT cell levels were also found to be increased in the synovial fluid as compared with the peripheral blood, suggesting that circulating MAIT cell deficiency is due to the migration of MAIT cells into the joint. Severity of arthritis induced by mBSA was reduced in mice depleted in MAIT cells. This data suggest that MAIT cells contribute to exacerbation of arthritis. Thus the present invention relates to the use of an agent capable of inhibiting the activation of MAIT cells for the treatment of rheumatoid arthritis

IPC Classes  ?

• A61K 31/11 - Aldehydes
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/60 - Salicylic acid; Derivatives thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

The invention relates to a sodium layered oxide of formula I: NaxM1a+i-y-z-nM2b+yM3c+zM4d+nO2, wherein: M1a+, M2b+, M3c+and M4d+ are different transition metal ions or mixtures thereof, x is a number ranging from 0.5 to less than 1; y, z and n are numbers ranging from 0.01 to 0.85; y + z + n is less than 1; a, b, c and d are the respective oxidation number of the transition metal ions M1, M2, M3 and M4, respectively; and the cumulative oxidation state of transition metal ions a*(1-y-z-n)+(b*y)+(c*z)+(d*n) is equal to 4-x; and wherein said sodium layered oxide of formula I is not P2- Na2/3Ni1/4Mn1/2Ti1/6Zn1/12O2, P2-Na2/3Ni1/4Mn1/2Ti1/6Mg1/12O2, or P2-Na2/3Ni1/4Mn1/2Ti1/6Mg1/12O2.

IPC Classes  ?

• C01G 53/00 - Compounds of nickel

Abstract

24 244 olefin and/or other hydrocarbons, comprising a step of reaction under direct induction heating, with a metal-free carbon material as defined in anyone of the claims, at temperature less than or equal to 800 °C.

IPC Classes  ?

• C10B 19/00 - Heating of coke ovens by electrical means
• C10B 53/07 - Destructive distillation, specially adapted for particular solid raw materials or solid raw materials in special form of synthetic polymeric materials, e.g. tyres
• C10G 1/10 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal from rubber or rubber waste
• H05B 6/10 - Induction heating apparatus, other than furnaces, for specific applications
• C10B 57/06 - Other carbonising or coking processes; Features of destructive distillation processes in general using charges of special composition containing additives
• C10G 1/00 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal
• C10G 15/08 - Cracking of hydrocarbon oils by electric means, electromagnetic or mechanical vibrations, by particle radiation or with gases superheated in electric arcs by electric means or by electromagnetic or mechanical vibrations
• H05B 6/06 - Control, e.g. of temperature, of power

Abstract

A method for controlling a system of quantum objects and associated device The invention relates to a method for controlling a system (10) of quantum objects (12), the method comprising the following steps: - identifying target quantum object(s) of the system (10) of quantum object(s), and - applying a control signal on at least the target quantum object(s) to realize a controlled quantum operation on the target quantum object(s), the control signal being a standing light wave having an amplitude and a phase, the phase being spatially uniform over some regions of space, the standing light wave being applied such that the position of each target quantum object coincides with a region of spatially uniform phase.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G01R 33/00 - Arrangements or instruments for measuring magnetic variables
• G04F 5/14 - Apparatus for producing preselected time intervals for use as timing standards using atomic clocks

Abstract

The present application relates to a writing instrument comprising a writing tip and an ink reservoir connected to the writing tip, wherein the ink reservoir is sized to contain at least 100 µl of ink and contains an aqueous gel ink, comprising metal nanoparticles as coloring agent, wherein said metal nanoparticles essentially consist of metal and said metal is chosen from silver, gold, aluminum and/or copper, and a dispersing agent; wherein metal nanoparticles are contained within the aqueous gel ink in an amount of 0.5 – 2.5 wt.-%, relative to the total weight of the ink; and wherein the writing instrument is configured to dispense 150 – 800 mg/100m.

IPC Classes  ?

• C09D 11/17 - Writing inks characterised by colouring agents
• C09D 11/18 - Writing inks for use in ball-point writing instruments

Abstract

The present disclosure relates to a functionalized polymer, for use in treating a disease correlated with heavy metal-induced toxicity or heavy metal-induced carcinogenicity in a subject in need thereof, wherein said functionalized polymer is soluble in aqueous solution, has a weight average molecular mass between 30 kDa and 5000 kDa, and wherein a part of the monomeric units are functionalized with a chelating moiety, wherein therapeutically efficient amount of said functionalized polymer is administered orally to the subject.

IPC Classes  ?

• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• A61K 31/718 - Starch or degraded starch, e.g. amylose, amylopectin
• A61K 31/722 - Chitin; Chitosan
• A61P 35/00 - Antineoplastic agents
• A61P 39/04 - Chelating agents
• A61K 31/726 - Glycosaminoglycans, i.e. mucopolysaccharides

Abstract

Here the inventors applied PDAC-derived CAF secretome on pancreatic cancer cells and evaluated Sig-1R implication in stromal cues integration by PCC from signaling transmission to biological outcomes, at the cellular and physiological level. They demonstrated that the loss of Sig-1R in epithelial cells inhibits stromal-induced tumor growth and metastatic process. Thus, the inventors demonstrate that Sig-1R is a key actor of the dialog between stromal and cancer cell compartments The present invention relates to method for the treatment of pancreatic cancer in a patient in need thereof comprising a therapeutically effective amount of a Sig-1R ligand.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents

Abstract

Pancreatic Ductal Adenocarcinoma (PDAC) still represents a therapeutic dead-end. The inventors report that the K+ channel SK2 is stimulated by secreted cues from cancer-associated- fibroblasts (CAF) leading to the activation of an Integrin-EGFR-AKT signaling axis which participates to the acquisition of pro-metastatic features. The inventors show that SK2 acts as a pivotal signaling regulator as being both a direct target of AKT and an amplifier of AKT- downstream transduction. The present invention relates to a method of treatment of pancreatic cancer in a patient in need thereof comprising a therapeutically effective amount of SK2 inhibitor.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 35/00 - Antineoplastic agents
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants

Abstract

The present invention belongs to the field of nanoporous materials, in particular metal organic frameworks (MOFs) and Lewis-based gas delivery and/or slow release, or the detection of Lewis-based gas(es) in gases or liquid streams. The present invention relates, inter alia, to a new ultra-microporous crystalline metal organic framework solid ( comprising bisphosphonic acid ligands (also refered to as Phosphonate MOF), such as MIP-210(M) and uses thereof as a carrier in Lewis-based gas (such as NO) delivery. The invention also relates to controlled release of the Lewis-based gas in wounds, for example by topical application. The invention also encompasses a synthetic method for producing the new ultra- microporous crystalline metal organic framework solid of the invention. The MOFs of the present invention can be used in various applications such as gas carrier and/or for the controlled release of gas. The MOFs of the present invention thus are very versatile and have therapeutic and non therapeutic applications.

IPC Classes  ?

• C07F 15/02 - Iron compounds
• A61L 15/00 - Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• B01D 53/00 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols
• B01D 53/94 - Chemical or biological purification of waste gases of engine exhaust gases by catalytic processes
• C07F 9/38 - Phosphonic acids (R—P(:O)(OH)2); Thiophosphonic acids

Abstract

The present invention concerns an aqueous solution comprising at least one synthetic (co)polymer, wherein said (co)polymer comprises at least one (L)-proline or (D)-proline monomer unit, wherein said (co)polymer exhibits a temperature-driven phase change involving aggregation on heating which is reversible on cooling and has a hysteresis greater than or equal to 20°C.

IPC Classes  ?

• C08J 3/05 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media from solid polymers
• C08K 3/16 - Halogen-containing compounds
• C08L 77/04 - Polyamides derived from alpha-amino carboxylic acids
• G01K 11/06 - Measuring temperature based on physical or chemical changes not covered by group , , , or using melting, freezing, or softening

Abstract

The invention concerns a sterile enclosure (2) intended for a printing of a biological three- dimensional structure, the sterile enclosure comprising : - a rigid top plate (4),5 - a rigid base plate (6) comprising a main face (16) intended to receive a biological three- dimensional structure, - a flexible side wall (8) fixed to the top plate and to the base plate to form an hermetically closed casing (10) delimiting an interior chamber (11), - a puncturable membrane (22) or a needle adapter arranged on the top plate, - a stretcher arm (36) articulated to the top plate and to the base plate, the flexible side wall and the stretcher arm being conform to allow the move of the top plate with respect to the base plate in three perpendicular directions (X,Y,Z); the at least one stretcher arm being elastic and pushing the top plate apart from the base plate.

IPC Classes  ?

• B33Y 70/00 - Materials specially adapted for additive manufacturing
• B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/26 - Inoculator or sampler

Abstract

The invention concerns a sterile enclosure (2) and a method of printing and culturing a three-dimensional biological structure in the sterile enclosure. The sterile enclosure comprising: - a base wall (10), - a flexible side wall (8); the side wall forming with the base wall (10) a flexible casing (12) delimiting an interior chamber (14), - a fluid inlet port (22) and a fluid outlet port (24) which allow the circulation of a culture media, - a needle adapter (4) fixed to the flexible side wall (8), the needle adapter (4) holding a printing needle (6), the flexible casing protecting a biological three-dimensional structure against contamination and authorizing at the same time the move of the needle adapter (4) in three directions during a printing of a biological three-dimensional structure in the interior chamber.

IPC Classes  ?

• B33Y 70/00 - Materials specially adapted for additive manufacturing
• B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/26 - Inoculator or sampler

Abstract

The invention concerns a sterile enclosure (91) comprising a container (92) and a printing needle holder device (58) fixed to the container. The container comprising a base wall (92), a side wall (94), the side wall and the base wall delimiting an interior chamber, one inlet port and outlet port and an aperture (24). The printing needle holder device (58) comprising a needle adapter, a printing needle and a flexible sheath having a first end edge fixed to the needle adapter and a second end edge fixed to the aperture of the container, a three dimensional biological structure being intended to be printed on the base wall (92), the interior chamber being intended to receive a cell culture media.

IPC Classes  ?

• B33Y 70/00 - Materials specially adapted for additive manufacturing
• B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
• B29C 64/209 - Heads; Nozzles
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/26 - Inoculator or sampler

Abstract

minmaxeffectiveeffective which is comprised between 0.1 and 1.9, ZT being the figure of merit of the microsensor, and T being the measurement temperature.

IPC Classes  ?

• G01J 5/04 - Casings
• G01J 5/12 - Radiation pyrometry, e.g. infrared or optical thermometry using electric radiation detectors using thermoelectric elements, e.g. thermocouples

Abstract

The present invention relates to the field of neuromuscular disorders (NMDs) and corresponding quantification methods. There indeed remains a strong need for novel drugs for the treatment and prevention of neuromuscular disorders. The inventors showed that the compounds according to the invention allow restoring locomotion and cellular related parameters: neuromuscular junctions structure, in particular by improving AChR clustering, and/or by increasing the co-localization of presynaptic nerve terminals and AChR microclusters, and/or by rescuing axonal outgrowth, in an individual with a neuromuscular disorder. In particular, the present invention relates to new compounds suitable for treating and/or preventing a neuromuscular disorder in an individual in need thereof. The present invention also relates to a method for automating the quantification of axons and/or neuromuscular junctions in a whole organism or in a biological sample and to a method for the identification of a compound able to prevent and/or treat a neuromuscular disorder in an individual in need thereof.

IPC Classes  ?

• A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/18 - Sulfonamides
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/277 - Nitriles; Isonitriles having a ring, e.g. verapamil
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/4045 - Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/417 - Imidazole-alkylamines, e.g. histamine, phentolamine